Pharmaceutical company Biota (ASX:BTA) has acquired the drug development assets of two companies for a combined $11.4 million in cash and shares.
Biota said it would purchase the drug development assets of Boston-based MaxThera for US$1.5 million ($1.61 million), with US$1.2 million to be paid out in cash, and the rest in Biota shares.
The company will also gain control of the drug discovery wing of Oxford’s Prolysis for $10.8 million in new-issue Biota shares, as well as up to 15% of the milestone and royalties received by Biota.
Speaking at the AGM today, CEO Peter Cook said he was “excited” about the company’s prospects for FY10 and beyond.
Join the CIO Australia group on LinkedIn. The group is open to CIOs, IT Directors, COOs, CTOs and senior IT managers.